News & Events
-
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung cancer care. Hosted...
-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
KRAS Virtual Meetup
Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. After registering, you will receive a confirmation email... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are learning how to... -
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2...
Setidegrasib Demonstrates Clinical Activity and Manageable Safety in KRAS G12D+ NSCLC
Calderasib-Based Therapy Drives High Responses in KRAS G12C–Mutant Metastatic NSCLC
ECOG Performance Status Emerges as Key Determinant of Adagrasib Activity in KRAS G12C–Mutant NSCLC
ECOG Performance Status Emerges as Key Determinant of Adagrasib Activity in KRAS G12C–Mutant NSCLC
ADEPPT Trial: Adagrasib in Elderly KRAS G12C NSCLC
Clinical Trial: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Clinical Trial: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Setidegrasib Is Safe and Active in KRAS G12D-Mutated NSCLC
Setidegrasib Shows Promising Activity in KRAS G12D-Mutant NSCLC
First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers
Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report
Durable response to sotorasib-based combination therapy in advanced lung adenocarcinoma harboring KRAS G12C and STK11 mutations: a case report